Stock Selection: GPT-6's picks for 2026-11-02
GPT-6 picked MAR, UAL, IDXX, XPEV, PLTR for a 1-day horizon. Portfolio return vs SPY: +0.05%. Picks that beat SPY: 60%.
| Experiment | Stock Selection |
|---|---|
| Model | GPT-6 |
| Prompt version | stock-selection-v8 |
| Asked | |
| Horizon | 1-day |
| Measured from | 2026-11-02 |
| Measured to | 2026-11-03 |
| Benchmark | SPY |
| Status | Settled |
| Portfolio return vs SPY | +0.05% |
| Picks that beat SPY | 60% |
| Benchmark return | -0.98% |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | MAR | +1.55% | 69% | +2.53% | Yes |
| 2 | UAL | -1.95% | 65% | -0.97% | No |
| 3 | IDXX | +4.38% | 63% | +5.36% | Yes |
| 4 | XPEV | -0.87% | 58% | +0.11% | Yes |
| 5 | PLTR | -7.75% | 53% | -6.77% | No |
The model's market view
Cautiously bullish for the November 2–3 forecast window, with selective opportunities to outperform SPY. U.S. equities are recovering from Friday's technology-led selloff, supported by falling crude oil prices and renewed hopes for U.S.-Iran diplomacy. Lower energy costs particularly favor airlines and travel companies. Strong quarterly earnings and upward guidance revisions provide company-specific catalysts that may persist into the next session. However, November 3 midterm elections, uncertainty about AI capital expenditures, and major after-hours earnings announcements create substantial overnight volatility risk. The selections prioritize confirmed positive earnings surprises, improving operating fundamentals, and identifiable short-term catalysts rather than broad index exposure. Each security receives a 20% portfolio weight. Confidence estimates reflect relative outperformance probabilities, not guaranteed positive absolute returns.
Why each pick
MAR
Marriott International is the highest-conviction selection because its November 2 third-quarter earnings release provides a confirmed positive catalyst. Worldwide revenue per available room increased 6.5%, including 7.4% growth in the United States and Canada. Adjusted EPS reached $3.02, compared with $2.47 one year earlier. Management raised its full-year global RevPAR growth outlook to 4.5%–5.0%, supported by resilient travel demand and strong execution. The company also reported a record development pipeline exceeding 634,000 rooms. The researched intraday quote of $418.40 reflects an approximately 4.7% advance, indicating a favorable initial market response. The thesis is that earnings-related institutional demand and upward estimate revisions can sustain relative strength through the next trading session. Risks include profit-taking following the initial rally, Marriott's elevated valuation, geopolitical disruptions to travel, and an unexpectedly weak broader market. The reference price is a delayed November 2 intraday quote, not the October 30 close.
UAL
United Airlines is positioned to benefit disproportionately from the sharp decline in crude oil prices associated with renewed diplomatic expectations concerning Iran. Fuel represents a significant airline operating expense, making sustained lower petroleum prices favorable for prospective margins and investor sentiment. The company also benefits from an established international route network and exposure to premium travel demand. Its recent stock-price recovery suggests improving momentum. The researched November 2 quote of $106.52 represents a gain from the October 30 closing price of $104.24. The one-session thesis is that continued relief in oil prices and renewed demand for travel-sensitive equities can help UAL outperform SPY. Risks include a reversal in crude prices, renewed geopolitical tensions, disappointing airline profitability, labor and operating costs, and profit-taking following recent gains. The reference price is an intraday quote retrieved from a market-data listing.
IDXX
IDEXX Laboratories reported a strong third quarter on November 2, with revenue increasing 10% to approximately $1.214 billion and diluted EPS reaching $4.01, an 18% reported increase. Companion Animal Group diagnostics recurring revenue grew 11%, supported by testing volumes, innovation, and instrument placements. Management raised its 2026 revenue outlook to $4.741–$4.767 billion and its EPS outlook to $14.96–$15.16. These results support a positive earnings-revision cycle following the stock's 4.3% decline on October 30. A verified November 2 premarket quote showed shares at $592.00, approximately 7.4% above the previous close. The thesis is that stronger recurring diagnostics growth and upward guidance revisions can sustain positive relative momentum. Risks include weaker veterinary clinic visits, premium valuation, volatility following the earnings gap, and profit-taking after the initial reaction. A reliable regular-session intraday quote could not be verified, so the reference price is the most recent identifiable premarket trade rather than an asserted live quote.
XPEV
XPeng has a company-specific momentum catalyst following its report of 50,237 vehicle deliveries in October 2026, representing approximately 20% year-over-year growth. Strong delivery performance can improve expectations for fourth-quarter revenue, manufacturing scale, and operating leverage. The stock was among November 2's notable early gainers, and the researched intraday quote of $9.655 represented an advance of approximately 7% relative to the previous session's reference level. The short-horizon thesis is that stronger delivery data, improving investor sentiment toward Chinese electric-vehicle manufacturers, and favorable momentum could sustain outperformance into November 3. Risks include intense Chinese EV pricing competition, potential margin compression, trade restrictions, currency fluctuations, and a rapid reversal after the initial rally. The reference price is a November 2 intraday market-data quote.
PLTR
Palantir Technologies is a higher-risk earnings-catalyst selection. The company is scheduled to announce third-quarter 2026 results after the November 2 market close, placing the announcement directly inside the forecast window. Market expectations include approximately $2.18 billion in quarterly revenue, implying substantial year-over-year growth. Palantir has an established record of earnings beats, and recent analyst target increases indicate continued interest in its commercial AI platforms and government software contracts. Shares declined approximately 6.3% on October 30, potentially creating room for a rebound if results and forward guidance exceed already elevated expectations. The positive thesis depends on accelerating commercial adoption, sustained government demand, and strong revenue guidance. Risks are substantial: expectations may already reflect aggressive growth, the valuation is demanding, and even strong reported results could trigger selling if guidance disappoints. The researched $186.70 reference is an earlier November 2 intraday quote; a more recent regular-session trade could not be verified. This is the lowest-confidence selection because the outcome is highly dependent on an unreleased earnings announcement.
Other models on the same run
| Model | Picks | Portfolio return vs SPY | Picks that beat SPY |
|---|---|---|---|
| GPT-6.1 Sol | DAL, MAR, NVDA, AVGO, IDXX | +2.17% | 100% |
| Claude Opus 5.5 | MAR, EL, SMH, MU, UAL | +0.02% | 40% |
| Claude Sonnet 5.5 | AMD, NVDA, PLTR, AMZN, DAL | -1.58% | 40% |
| Muse Spark 1.1 | TSLA, NVDA, PLTR, QQQ, AAPL | -2.23% | 20% |
| Perplexity | RIVN, MAR, IDXX, REGN, GPN | +1.86% | 80% |
| Gemini 3 Pro | UAL, CCL, DAL, VRT, XLI | +0.63% | 60% |
| Grok 4.7 | IDXX, RIVN, ULCC, NVDA, JBLU | -0.31% | 60% |
| DeepSeek | OKTA, AAPL, QQQ, PLTR, RIVN | -2.77% | 0% |
Written up on ForecastNest Insights: Stock Selection: GPT-6's picks for 2026-11-02.
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.